Potassium Disorders — Written Clinical Reasoning

Prompt 1 — Severe hyperkalaemia in a complex CKD patient

Question

Summarise this patient's problems, explain the immediate emergency management in the first 30 minutes with specific drugs and doses, identify the cause of the hyperkalaemia, outline the decision about whether and when to dialyse, and describe the subsequent management and monitoring plan including the cardiorenal trade-offs. [1]

Model answer

Problem list (prioritised): [1]

1. Severe hyperkalaemia — K+ 7.6 mmol/L — with a pre-terminal ECG (QRS 150 ms, sine-wave morphology) — this is a cardiac emergency with imminent risk of ventricular fibrillation or asystole.
2. Metabolic acidosis — pH 7.28, bicarbonate 16 — a contributing factor to the hyperkalaemia through transcellular shift, and a feature of his CKD.
3. Bradycardia (HR 56) — likely a consequence of the hyperkalaemia acting on the conducting system.
4. Stage 3b CKD with a cardiorenal drug regimen (sacubitril/valsartan, spironolactone, empagliflozin, frusemide, bisoprolol) — the structural and pharmacological substrate for impaired potassium excretion.
5. Recent gastroenteritis with volume depletion and reduced intake — the precipitant, reducing distal sodium delivery and potassium excretion.
6. Heart failure with reduced ejection fraction and ischaemic heart disease — the indication for his mortality-reducing drugs and the context for his cardiovascular risk.
7. Type 2 diabetes on metformin with an acute kidney injury on top of CKD — metformin should be held during acute illness and AKI given the risk of lactic acidosis.
8. Encephalopathy — likely a combination of acidosis, the underlying illness, and the electrolyte disturbance; assess for alternative causes (sepsis, intracranial event). [1]

Immediate management in the first 30 minutes — the four pillars: [1]

First, secure the patient and confirm the value. ABC assessment, high-flow oxygen if hypoxic, continuous cardiac monitoring, two large-bore cannulae, and an immediate repeat of the potassium as a venous or arterial blood gas to confirm the value and exclude pseudohyperkalaemia (less likely here given the ECG changes, but the discipline matters). I would obtain a group and hold and send full blood count, urea and electrolytes including magnesium, liver function, troponin, and venous lactate. [1]

Pillar 1 — Stabilise the myocardium. Given the sine-wave ECG, I give calcium gluconate 10 mL of 10% (2.25 mmol of calcium) intravenously over 2 to 5 minutes, with continuous ECG monitoring, and repeat once after 5 minutes if the ECG changes persist. Calcium raises the threshold for excitation and reverses the membrane effect of hyperkalaemia within 1 to 3 minutes; it does not lower the potassium but buys time. I would re-dose every 30 to 60 minutes if ECG changes recur while awaiting definitive therapy [7].

Pillar 2 — Shift potassium into cells. I give 10 units of rapid-acting (soluble) insulin with 25 g of intravenous dextrose (25 mL of 50% dextrose over 15 to 30 minutes, or as a bolus), which stimulates the Na+/K+-ATPase and lowers the potassium by 0.5 to 1.2 mmol/L over 30 to 60 minutes, with effect for 4 to 6 hours. I combine this with salbutamol 10 to 20 mg nebulised, which is additive and lowers the potassium by a further 0.5 to 1.0 mmol/L. Because he is acidaemic, I add sodium bicarbonate 50 mmol of 8.4% intravenously over 15 to 30 minutes, which is effective in this context (bicarbonate is confined to the acidotic patient and not effective as monotherapy in non-acidotic hyperkalaemia). I would check a blood glucose at baseline, at 30 minutes, at 1 hour, then hourly for 4 to 6 hours, because hypoglycaemia is the commonest serious adverse event of insulin-dextrose, occurring in up to 20 percent of patients, sometimes delayed, and a lower-dose insulin regimen (5 units) lowers potassium as effectively with less hypoglycaemia [5].

Pillar 3 — Remove potassium. I give frusemide 80 mg intravenously (he has residual renal function and is not described as oliguric) to promote potassium excretion. I start an oral potassium binder — sodium zirconium cyclosilicate 10 g three times daily for the first 48 hours (faster onset than patiromer; HARMONIZE demonstrated a rapid reduction [4]) — with a plan to step down to maintenance dosing. I would avoid sodium polystyrene sulfonate (resonium) given the risk of intestinal necrosis, especially if he has any ileus.

Pillar 4 — Address the cause. I hold the sacubitril/valsartan and spironolactone immediately, hold the metformin (AKI risk), and review the empagliflozin (also a contributor to volume depletion and euglycaemic ketoacidosis risk). I correct the volume depletion with cautious isotonic saline (mindful of his heart failure — small boluses, reassess). I treat the acidosis with bicarbonate as above. I reassess his medications once the potassium is controlled. [1]

The dialysis decision. The indications for urgent haemodialysis in hyperkalaemia are: refractory hyperkalaemia despite medical therapy, severe hyperkalaemia with ECG changes in a patient with oligoanuria or end-stage CKD, and ongoing potassium release (rhabdomyolysis, tumour lysis). This patient presented with a pre-terminal ECG but has stage 3b CKD (not oligoanuric) and has good urinary output expected with frusemide. I would give the full medical protocol above first, reassess the potassium and ECG at 1 to 2 hours, and call the nephrology team early. If the potassium fails to fall below 6.5, or the ECG fails to improve, or he becomes oliguric, I would proceed to haemodialysis via temporary vascular access. Continuous renal replacement therapy (CVVHDF) would be preferred if he is haemodynamically unstable. I would warn the team of rebound — the insulin-dextrose wears off at 4 to 6 hours, and if the underlying cause persists, the potassium will rise again; ongoing removal (binder, diuretic, dialysis) is essential. [1]

Subsequent management and monitoring plan. I would admit him to high dependency with continuous cardiac monitoring. I would recheck the potassium at 1, 2, 4, 6, then 12 hours during the acute phase, watching for rebound. I would monitor the blood glucose hourly for 4 to 6 hours after insulin-dextrose. Once the potassium is below 6.0 and the ECG has normalised, I would start to plan the cardiorenal trade-off: the sacubitril/valsartan, spironolactone, and empagliflozin are each proven to reduce mortality and hospitalisation in HFrEF and CKD, and ceasing them permanently worsens his outcome. The modern approach is to reintroduce the RAAS inhibitor and MRA at a lower dose once the potassium is controlled, maintain the patient on an oral potassium binder (patiromer or SZC) to enable continuation, and monitor the potassium and renal function closely — typically 1 to 2 weeks after reinitiation and dose changes [1][3]. The binder is the bridge that allows continuation of mortality-reducing therapy. I would address his diabetes (continue metformin only after the AKI resolves; the empagliflozin is cardiorenal-protective but should be held during acute illness), review his heart failure and volume status, and investigate the precipitant (the gastroenteritis with volume depletion and reduced intake is the trigger superimposed on the drug regimen). I would also arrange a diabetes and heart failure review and ensure he has a sick-day plan for future illness (hold the RAAS inhibitor, SGLT2 inhibitor, and diuretics during acute illness — the "Sick Day Guidance").

Prompt 2 — Refractory hypokalaemia and the workup of normotensive hypokalaemia

Question

A 26-year-old woman presents with chronic muscle cramps, fatigue, and intermittent nocturia. She is normotensive (BP 110/68). Bloods show potassium 2.8 mmol/L, magnesium 0.48 mmol/L, bicarbonate 34 mmol/L, creatinine 72. A 24-hour urine shows potassium 42 mmol/day, calcium 1.5 mmol/day (low), chloride 60 mmol/day. Plasma renin and aldosterone are both elevated. Outline the differential diagnosis, the single most likely diagnosis and the reasoning, the further confirmatory tests, and the principles of long-term management. [1]

Model answer

Differential diagnosis of normotensive hypokalaemia with metabolic alkalosis and renal potassium wasting: [1]

The defining pattern is a hypokalaemic, alkalotic, normotensive young woman with inappropriately high urinary potassium (greater than 30 mmol/day despite hypokalaemia), indicating renal potassium wasting. The differential is: [1]

1. Gitelman syndrome — autosomal recessive loss of the thiazide-sensitive Na-Cl cotransporter in the distal convoluted tubule; presents in adolescence or adulthood; hypokalaemia, metabolic alkalosis, hypomagnesaemia, hypocalciuria, normal to low blood pressure, high renin and aldosterone.
2. Bartter syndrome — loss of the Na-K-2Cl cotransporter in the thick ascending limb; presents in childhood; hypokalaemia, metabolic alkalosis, hypercalciuria (distinguishing), normal to low blood pressure, high renin and aldosterone; often more severe with growth failure and polyhydramnios history.
3. Diuretic abuse — surreptitious loop or thiazide use; mimics Bartter or Gitelman; a toxicology screen of the urine resolves it.
4. Persistent vomiting — causes hypokalaemia, alkalosis, and high urine potassium (through secondary hyperaldosteronism), but with a low urine chloride (less than 20 mmol/day), not the high chloride seen here.
5. Laxative abuse — hypokalaemia with metabolic acidosis (not alkalosis) from GI bicarbonate loss; excluded by the alkalosis. [1]

Single most likely diagnosis: Gitelman syndrome. The reasoning rests on four features: the hypocalciuria (24-hour urine calcium 1.5 mmol/day is low), which is the key discriminator from Bartter syndrome (which causes hypercalciuria); the hypomagnesaemia (a hallmark of Gitelman, less prominent in Bartter); the presentation in adulthood (Gitelman presents later, Bartter in childhood); and the elevated renin and aldosterone with normotension, confirming the inherited tubulopathy pattern rather than primary aldosteronism (which is hypertensive with suppressed renin) [8]. The high urine chloride (60 mmol/day) and the high urine potassium confirm ongoing renal loss in the setting of hypokalaemia.

Further confirmatory tests: [1]

• Genetic testing for mutations in SLC12A3 (the gene encoding the Na-Cl cotransporter, mutated in 80 percent of Gitelman) and CLCNKB (which can cause a Gitelman-like phenotype). Genetic confirmation is the gold standard.
• Repeat the 24-hour urine for calcium and magnesium to confirm the pattern, and assess the magnitude of ongoing losses.
• Exclude surreptitious diuretic use with a urine diuretic screen, to rule out the mimicking drug-induced cause.
• Assess for complications — a transtubular potassium gradient, a renal ultrasound (to exclude nephrocalcinosis, which is a feature of Bartter but not Gitelman), and a bone density (chronic magnesium and potassium depletion can affect bone).
• ECG for QT prolongation from hypokalaemia and hypomagnesaemia. [1]

Principles of long-term management: [1]

• Lifelong potassium and magnesium supplementation — oral potassium chloride (slow-release, 20 to 40 mmol two to three times daily) and oral magnesium (magnesium oxide or aspartate, often in large doses). Magnesium replacement is the cornerstone; without it, the hypokalaemia is refractory.
• A potassium-sparing diuretic — amiloride 5 to 10 mg daily, or spironolactone/eplerenone — to reduce renal potassium and magnesium loss. Amiloride is preferred because it lacks the hormonal side effects of spironolactone.
• Liberal salt intake (patients with Gitelman are chronically volume-depleted and benefit from dietary sodium), and a high-potassium diet.
• Patient education — the condition is lifelong; symptoms can be controlled but the electrolyte disturbance persists; dehydration and intercurrent illness worsen the losses; women of childbearing age should be counselled about pregnancy (which is generally well-tolerated with supplementation).
• Monitoring — periodic potassium, magnesium, and creatinine; ECG if symptomatic; bone density periodically.
• Prognosis — Gitelman syndrome has a better prognosis than Bartter syndrome, with most patients living normal lifespans with treatment, though quality of life can be affected by fatigue, cramps, and chondrocalcinosis (from chronic hypomagnesaemia). [1]

The cardinal teaching point in this stem is the calcium discriminator: hypocalciuria and hypomagnesaemia with a normotensive hypokalaemic alkalosis is Gitelman; hypercalciuria is Bartter [8][2].